<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="797">
  <stage>Registered</stage>
  <submitdate>27/09/2005</submitdate>
  <approvaldate>4/10/2005</approvaldate>
  <actrnumber>ACTRN12605000583640</actrnumber>
  <trial_identification>
    <studytitle>MRI to monitor the effect of zoledronic acid in erosive psoriatic arthritis</studytitle>
    <scientifictitle>A randomised placebo controlled study to evaluate the effects of zoledronic acid in reducing the progression of erosions in psoriatic arthritis.</scientifictitle>
    <utrn />
    <trialacronym>ZAPA study</trialacronym>
    <secondaryid>Protocol No. CZOL446HNZ02</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Psoriatic arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Zoledronic acid for treatment of erosive psoriatic arthritis: double blind randomised placebo controlled study. One year duration ( 4 IV injections at 3 month intervals).</interventions>
    <comparator />
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To monitor MRI scans of dominant wrist and hand for change in bone erosion</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To monitor MRI scans of dominant wrist and hand for change in bone oedema score</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To monitor change in Sharp score (hands and feet) - both total and separately the erosion score component.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To examine blood and urinary markers of bone turnover at 6 monthly intervals and compare these between the 2 groups.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To examine bone mineral density (BMD) in the two groups.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To examine osteoclast function at baseline and after 12 months in the 2 groups.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Psoriatic arthritis (according to Vasey and Espinoza criteria)Erosive PsA (bone lysis/ erosion peripheral joints on XR confirmed by a radiologist). Disease duration &gt; 6 months. Suitable for MR scan*   Adequate contraception if applicable DMARD, on a stable dose for 8 weeks prior to randomization Oral Prednisone no &gt; 10mg daily at least 3 swollen and 3 tender joints.</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Severe kidney, liver or heart disease Deranged calcium or Vit D levelsUveitis, Iritis, or chronic Conjunctivitis (or history of these conditions)Diabetic eye or kidney disease Uncontrolled diabetes, Hb1AC &gt; 10 % Cancer (metastatic cancer or cancer diagnosed &lt; 2 years ago)     Is pregnant or planning pregnancy Severe dental problems or current dental infection, recent or impending dental surgery within three months of enrolmentOrthopaedic surgery within 3 months      of enrolment Fractures (within the last 3 months) Use of Bisphosphonate therapy Participant in any  biologics trial within 6 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Pharmacy supplied with random order list by statistician.Sequence was concealed</concealment>
    <sequence>A block randomised list was computer generated using a programme written in SAS.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/08/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Auckland</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Auckland Medical Research Foundation</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Novartis</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Switzerland</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to investigate whether zoledronic acid is effective in slowing bone erosion/lysis in patients with psoriatic arthritis. Ã¿Â¢Ã¿Â¿Ã¿Â¿ comparison with placebo. Bone damage to be assessed using MRI scans and XRays. Secondary outcomes assessed include BMD, ositeoclast function and bone turnover markers.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Mutiregion ethics committee-Auckland Rotorua</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mutiregion ethics committee-Wellington</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Cecelia Tong</name>
      <address>Department of Rheumatology
Greenlane Clinical Centre
Building 7
Greenlane West
Auckland 3</address>
      <phone>+64 9 3797440 ext. 26671</phone>
      <fax />
      <email>CeceliaT@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Fiona McQueen</name>
      <address>Department of Molecular Medicine and Pathology
University of Auckland
Private Bag 92019
Auckland</address>
      <phone>+64 9 3737599</phone>
      <fax>+64 9 3754324</fax>
      <email>f.mcqueen@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>